10.27.25 -- STREAM Edition: Are There Countries You Should Avoid When Outsourcing?

Join 1,000+ pharma, biotech, and drug delivery professionals at the PODD: Partnership Opportunities in Drug Delivery Conference, October 27–28 in Boston. Featuring 10 technology tracks, pharma company spotlights, 1:1 partnering, and more. Attendees will also hear from leaders at companies including AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, GSK, Moderna, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and others. Register at PODDConference.com with code LSL20 for 20% off.

Discover how innovative technologies, global reach, and commitment to quality and patient centricity can deliver exceptional solutions for your oral solid dose needs.

Explore how SUREtechnology Platform™, powered by Selexis®, accelerates the development of complex biologics from early stages to first-in-human (FIH) trials, focusing on both speed and quality.

An experienced CDMO can empower developers to implement de-risking strategies that significantly improve both clinical and commercial outcomes for their biologic and bioconjugate programs.

Watch as experts delve into the implementation of Process Analytical Technology (PAT) for ADC and bioconjugation processes and the pros and cons of in(on)line testing for the conjugation process.

The regulatory or political environment can be different for drug development and manufacturing in countries around the globe. Is that a reason to avoid some? Our expert has his doubts.

Genome editing and iPSC technologies can speed up preclinical model creation, assay development, safety testing, and CMC consultation to streamline screenings and IND filing.

With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about our integrated facilities, project teams, and available capacity.